後眼病市場：按產品、按應用、按地區 - 規模、份額、展望、機會分析，2022-2028 年

後眼部疾病泛指視網膜、脈絡膜和視神經的疾病，主要包括青光眼、年齡相關性黃斑變性（AMD）和糖尿病視網膜病變（DR）。 治療儀主要用於治療眼後部疾病。

市場動態

眼後部疾病負擔的增加、糖尿病患病率的增加、老年人口的增加、對安全有效治療的需求增加、研究和開發活動的增加將導致全球成為預期推動眼病增長的主要因素市場。

例如，2021 年 12 月，AbbVie Inc.（Allergan）獲得美國食品和藥物管理局 (FDA) 的批准，將 1.25% 的 VUITY（鹽酸毛果芸香鹼滴眼液）用於治療老花眼。現在藥店可以通過處方購買.

此外，2020年6月，千住製藥與大塚製藥宣佈在國內上市治療青光眼和高眼壓症的“艾拉胺複方眼藥水”。

這項研究的主要特點

• 本報告對全球後眼疾病市場進行了深入分析，提供了以 2021 年為基準年的預測期 (2022-2028) 的市場規模和復合年增長率 (CAGR%)。我是這裡。
• 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
• 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
• 它根據以下參數（包括公司亮點、產品組合、主要亮點、財務業績和戰略）介紹了全球眼後部疾病市場的領先企業。
• 本研究涵蓋的主要公司包括 Novartis AG、Merck & Co. Inc.、F. Hoffmann-La Roche AG、AbbVie Inc (Allergan)、Alcon Inc.、Bausch Health Companies Inc.、Aerie Pharmaceuticals、Santen Pharmaceutical Co. Ltd.、Second Sight Medical Products Inc.、Rainbow Medical Ltd (Nano Retina) 和 Regeneron Pharmaceuticals Inc.
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 本研究報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球眼後部疾病市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按產品分類
  • 市場概況：按應用分類
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 眼後節疾病負擔增加
  • 嚴格的監管框架和政策
  • 對安全有效治療的需求不斷增長
• 影響分析
• 主要亮點
• 監管情景
• 產品發布和批准
• 害蟲分析
• 對 PORTER 的分析
• 合併/收購場景

第 4 章後節段疾病的全球市場——冠狀病毒 (COVID-19) 大流行的影響

• COVID-19 的流行病學
• 供應方和需求方分析
• 經濟影響

第 5 章全球眼後節疾病市場：副產品，2017-2028

• 藥物
• 設備

第 6 章。後節眼病的全球市場：按應用，2017-2028

• 黃斑變性
• 青光眼
• 糖尿病視網膜病變
• 其他用途

第 7 章按地區分列的後節段疾病全球市場，2017-2028

• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲
• 世界其他地方

第八章競爭格局

• Novartis AG
• Merck & Co. Inc.
• F. Hoffmann-La Roche AG
• AbbVie Inc（Allergan）
• Alcon Inc.
• Bausch Health Companies Inc.
• Aerie Pharmaceuticals
• Santen Pharmaceutical Co. Ltd.
• Second Sight Medical Products Inc.
• Rainbow Medical Ltd（Nano Retina）
• Regeneron Pharmaceuticals Inc.

第 9 章

• 調查方法
• 關於出版商

Posterior segment eye disease (PSED) is commonly defined as diseases of the retina, choroid & optic nerve and primarily include glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapeutic devices are primarily used in the treatment of the posterior segment eye disorders.

Market Dynamics:

Increase in burden of posterior segment eye disorders, increase in prevalence of diabetes, increase in geriatric population, rise in demand for safe and effective treatments, and increase in research and development activities are major factors expected to propel the growth of the global posterior segment eye disorders market over the forecast period.

For instance, in December 2021, AbbVie Inc. (Allergan) received the United States Food and Drug Administration (FDA) approval for VUITY (pilocarpine HCl ophthalmic solution) 1.25% to treat presbyopia and be available by prescription in pharmacies in the U.S.

Moreover, in June 2020, Senju Pharmaceutical and Otsuka Pharmaceuticals announced the launch of a new combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE Combination Ophthalmic Suspension, in Japan.

Key features of the study:

• This report provides in-depth analysis of the global posterior segment eye disorders market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global posterior segment eye disorders market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche AG, AbbVie Inc (Allergan), Alcon Inc., Bausch Health Companies Inc., Aerie Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Second Sight Medical Products Inc., Rainbow Medical Ltd (Nano Retina), and Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global posterior segment eye disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global posterior segment eye disorders market.

Detailed Segmentation:

• Global Posterior Segment Eye Disorders Market, By Product:
  • Drugs
  • Devices
• Global Posterior Segment Eye Disorders Market, By Application:
  • Macular Degeneration
  • Glaucoma
  • Diabetic Retinopathy
  • Other Applications
• Global Posterior Segment Eye Disorders Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Novartis AG
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc (Allergan)
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Aerie Pharmaceuticals
  • Santen Pharmaceutical Co. Ltd.
  • Second Sight Medical Products Inc.
  • Rainbow Medical Ltd (Nano Retina)
  • Regeneron Pharmaceuticals Inc.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Application
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increase in burden of posterior segment eye disorders
  • Stringent regulatory framework or policies
  • Increase in demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Posterior Segment Eye Disorders Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Posterior Segment Eye Disorders Market, By Product, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Posterior Segment Eye Disorders Market, By Application, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Glaucoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Diabetic Retinopathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Other Applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Posterior Segment Eye Disorders Market, By Geography, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc (Allergan)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alcon Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aerie Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Santen Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Second Sight Medical Products Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rainbow Medical Ltd (Nano Retina)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us